Physician profile
Bashar Salem
NPI 1841306958
$1,853.21
in general payments reported to CMS, 2019-2025
20 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $143 · 2021: $291 · 2022: $279 · 2023: $134 · 2024: $95.76 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $390.55 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $238.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.59 | 2019-2025 | Ofev |
| Verona Pharma, INC. | $146.78 | 2025 | Ohtuvayre |
| Genzyme Corporation | $126.42 | 2022-2025 | |
| Inspire Medical Systems, INC. | $126.08 | 2019 | |
| Astellas Pharma US INC | $87.99 | 2021 | |
| Insmed, INC. | $84.14 | 2019-2025 | Brinsupri, Arikayce |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Baxter Healthcare | $67.40 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $67.24 | 2022-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $59.89 | 2020-2021 | |
| Pulmonx Corporation | $51.82 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Advanced Respiratory, INC | $31.36 | 2019-2021 | |
| Ethicon INC. | $24.40 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $21.20 | 2020 | |
| Vapotherm INC | $17.50 | 2024 | Vapotherm |
| Merck Sharp & Dohme LLC | $12.89 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.92 | 2020 | |
| Inogen, INC. | $9.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.